share_log

8-K/A: Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates (Amendment)

8-K/A: Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates (Amendment)

8-K/A：Cassava Sciences报告2024年第二季度财务业绩和运营最新情况(修正)
美股SEC公告 ·  08/09 08:27

Moomoo AI 已提取核心信息

Cassava Sciences, Inc. has filed an amendment to its previously furnished Form 8-K report, originally submitted on August 8, 2024. The amendment, dated August 9, 2024, corrects an error in the diluted Net income (loss) per share for the six months ended June 30, 2024. The initial report incorrectly stated the figure as $(1.72), whereas the amended report presents the correct figure of $(0.28). This figure aligns with the data provided in the Company's quarterly report on Form 10-Q for the same period. The amendment clarifies that no other figures or information from the initial report are affected. The corrected financial information is furnished and not filed, meaning it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into any future filings under the Securities Act of 1933 or the Exchange Act.
Cassava Sciences, Inc. has filed an amendment to its previously furnished Form 8-K report, originally submitted on August 8, 2024. The amendment, dated August 9, 2024, corrects an error in the diluted Net income (loss) per share for the six months ended June 30, 2024. The initial report incorrectly stated the figure as $(1.72), whereas the amended report presents the correct figure of $(0.28). This figure aligns with the data provided in the Company's quarterly report on Form 10-Q for the same period. The amendment clarifies that no other figures or information from the initial report are affected. The corrected financial information is furnished and not filed, meaning it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, nor will it be incorporated by reference into any future filings under the Securities Act of 1933 or the Exchange Act.
Cassava Sciences提交了对其先前提交的2024年8月8日提交的8-K表单报告的修订。这份于2024年8月9日的修订纠正了截至2024年6月30日六个月的每股稀释净利润（亏损）的错误。初始报告错误地将数字声明为（1.72）美元，而修订后的报告呈现了正确的数字（0.28）美元。此数字与该公司同一时期提交的10-Q表格季度报告中提供的数据相一致。修订澄清了初始报告中没有其他数字或信息受到影响。修正后的财务信息是提交而非注册，这意味着它不受《1934年证券交易法》第18条的责任约束，也不会被纳入到任何未来根据《1933年证券法》或《交易法》提交的文件中。
Cassava Sciences提交了对其先前提交的2024年8月8日提交的8-K表单报告的修订。这份于2024年8月9日的修订纠正了截至2024年6月30日六个月的每股稀释净利润（亏损）的错误。初始报告错误地将数字声明为（1.72）美元，而修订后的报告呈现了正确的数字（0.28）美元。此数字与该公司同一时期提交的10-Q表格季度报告中提供的数据相一致。修订澄清了初始报告中没有其他数字或信息受到影响。修正后的财务信息是提交而非注册，这意味着它不受《1934年证券交易法》第18条的责任约束，也不会被纳入到任何未来根据《1933年证券法》或《交易法》提交的文件中。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间